Latest News and Press Releases

Ocean Biomedical’s Oncology Platform currently consists of 27 Patents Issued or Pending. Ocean Biomedical’s first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown...

Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria Therapeutics. Providence, RI, July 11, 2023 (GLOBE NEWSWIRE) --...

Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria ...

Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in multiple...

Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...

Providence, RI, June 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: “OCEA”), a next-generation biopharma company working to accelerate the development and commercialization of...

Patent for breakthrough approach to disrupting the malaria parasite’s life cycle adds to a growing global patent portfolio, with 25 patents issued and an additional 38 patents pending. ...

Providence, RI, June 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a new-era biopharma company working to accelerate the development and commercialization of scientifically...

Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on...

Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific co-founder, Dr. Jack A....